source
- The future of gray-market peptidesTwo days’ worth of debate among FDA advisory committee members and agency staff over whether compounding pharmacies should be able to make seven different peptides left me with some big ...
- Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage studyPemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Altimmune is going up against Eli Lilly and newcomer Baseline Therapeutics, among oth…